RxDoctor Payments Data

John Bunka, DO

Neurology · Kalamazoo, MINPI 1457611956

Payments from drug & device makers

$24,843in general payments, 2019–2025

Across 171 payments — averaging $145.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$23K
  • Supernus Pharmaceuticals, Inc.$783
  • Eisai Inc.$344
  • SK Life Science, Inc.$316
  • Neuropace, Inc.$126
  • Jazz Pharmaceuticals Inc.$107
  • plus $483 from 12 others

What the payments were for

  • Consulting fees$2,86212%
  • Speaking & faculty fees$17,12769%
  • Travel & lodging$1,4776%
  • Food & beverage$3,26813%
  • Education$1080%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,843 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$52,567
Medicare patients
242
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)17$200,544
BriviactBrivaracetam56$117,276
XcopriCenobamate29$66,623
VimpatLacosamide51$62,934
OnfiClobazam11$58,063
Nurtec OdtRimegepant Sulfate39$52,628
ValtocoDiazepam29$46,824
Oxtellar XrOxcarbazepine15$45,235
FycompaPerampanel17$42,771
UbrelvyUbrogepant30$34,509
Aimovig AutoinjectorErenumab-Aooe45$32,402
KeppraLevetiracetam12$28,643
Lacosamide178$26,148
Topiramate ErTopiramate17$23,378
Keppra XrLevetiracetam12$23,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat$54$180,210107 claims
SK Life Science, Inc.Xcopri$316$66,62329 claims
AbbVieUbrelvy, Qulipta$35$49,94644 claims
Neurelis, Inc.Valtoco$22,684$46,82429 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$783$45,23515 claims
Eisai Inc.Fycompa$344$42,77117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →